← Leaderboards
Tsui-Fen Chou
California Institute Of Technology
$6,181,325
Attributed
$11,415,155
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2016–22$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$11,415,155 · 5
By mechanism
R01$5,634,479 · 3
U44$5,612,276 · 1
R03$168,400 · 1
Top collaborators
- Paul Warren Sternberg5 shared
- Patricia I Dickson2 shared
- Charles Alexander Glass2 shared
- Jill Wood2 shared
- David Aaron Prober1 shared
Most similar at California Institute Of Technology
Same institution · by research overlap
- Thomas J. Meade$11,533,097
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsBaseMutationMutantAmino AcidsCellsAtp PhosphohydrolasePathway InteractionsMutateGeneticBindingAnimal ModelNovel TherapeuticsFibroblastsMediatingPhenotypeInheritedLeadAffectExperimental StudyAreaIntegral Membrane ProteinKnock-OutBrain
Grant awards (19)
Development and Validation of Therapy for Mucopolysaccharidosis III$2,435,870
U44 · FY2022 · NS
Dysregulation of p97/VCP disease mutants in IBM and FTLD-U$503,946
R01 · FY2022 · NS · contact PI
Phosphoproteomic Analyses of Understudied Protein Kinases that affect Zebrafish Sleep$168,400
R03 · FY2022 · TR
Dysregulation of p97/VCP disease mutants in IBM and FTLD-U$584,863
R01 · FY2021 · NS · contact PI
Dysregulation of p97/VCP disease mutants in IBM and FTLD-U$518,545
R01 · FY2020 · NS · contact PI
Cell adhesion mediated by LINKIN$373,501
R01 · FY2020 · HD
Dysregulation of p97/VCP disease mutants in IBM and FTLD-U$71,654
R01 · FY2020 · NS · contact PI
Cell adhesion mediated by LINKIN$373,501
R01 · FY2019 · HD
Dysregulation of p97/VCP disease mutants in IBM and FTLD-U$337,706
R01 · FY2019 · NS · contact PI
Using HTS to Identify Inhibitors of R155H-p97/VCP Mutant to treat IBMPFD/ALS$229,154
R01 · FY2019 · NS · contact PI
Dysregulation of p97/VCP disease mutants in IBM and FTLD-U$184,933
R01 · FY2019 · NS · contact PI
Using HTS to Identify Inhibitors of R155H-p97/VCP Mutant to treat IBMPFD/ALS$122,920
R01 · FY2019 · NS · contact PI
Development and validation of therapy for mucopolysaccharidosis III$3,176,406
U44 · FY2018 · NS
Dysregulation of p97/VCP disease mutants in IBM and FTLD-U$551,755
R01 · FY2018 · NS · contact PI
Cell adhesion mediated by LINKIN$373,501
R01 · FY2018 · HD
Using HTS to Identify Inhibitors of R155H-p97/VCP Mutant to treat IBMPFD/ALS$319,156
R01 · FY2018 · NS · contact PI
Cell adhesion mediated by LINKIN$373,501
R01 · FY2017 · HD
Using HTS to Identify Inhibitors of R155H-p97/VCP Mutant to treat IBMPFD/ALS$329,000
R01 · FY2017 · NS · contact PI
Cell adhesion mediated by LINKIN$386,843
R01 · FY2016 · HD